[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurolysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurolysis":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100634257","knee-osteoartritis-genicular-nerve-rf-ablation-vs-alcohol-neurolysis-100634257",false,"NCT07537335","Knee Osteoartritis Genicular Nerve RF Ablation vs Alcohol Neurolysis","Comparison of Genicular Nerve Radiofrequency Ablation and Neurolytic Alcohol Injection for Chronic Knee Osteoarthritis Pain: A Randomized Controlled Trial","GEN-AL-RF","Inclusion Criteria:\n\n* Age: Patients aged 45 to 85 years.\n* Diagnosis: Chronic knee pain for at least 6 months diagnosed with knee osteoarthritis according to American College of Rheumatology (ACR) criteria.\n* Radiological Grade: Grade 3 or 4 according to the Kellgren-Lawrence (K-L) classification.\n* Pain Severity: Baseline Numerical Rating Scale (NRS) score of 5 or higher.\n* Failure of Conservative Treatment: Inadequate response to conservative treatments (e.g., physical therapy, NSAIDs, or intra-articular injections) for at least 3 months.\n* Positive Diagnostic Block: At least 50% reduction in pain for minimum 24 hours following a prognostic genicular nerve block with local anesthetic.\n\nExclusion Criteria:\n\n* Previous Surgery: History of knee arthroplasty or major knee surgery on the affected side.\n* Specific Conditions: Presence of inflammatory arthritis (e.g., rheumatoid arthritis), gouty arthritis, or active infection at the injection site.\n* Neurological Deficit: Severe neurological or psychiatric disorders that may interfere with pain assessment.\n* Coagulopathy: Uncontrolled bleeding disorders or use of anticoagulant therapy that cannot be temporarily discontinued.\n* Recent Injections: Intra-articular steroid or hyaluronic acid injection within the last 3 months.\n* Allergy: Known allergy to local anesthetics, contrast agents, or ethyl alcohol.\n* Pacemaker: Presence of a cardiac pacemaker or implanted electronic device (specifically for the RFA group).","ALL","45 Years","80 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","The GEN-AL-RF study is a randomized controlled trial designed to compare the clinical efficacy of two interventional techniques for managing chronic knee pain due to osteoarthritis. The study focuses on genicular nerve radiofrequency (RF) ablation versus neurolytic alcohol injection for pain blockade.\n\nPatients diagnosed with knee osteoarthritis are randomly assigned to either the RF ablation group or the neurolytic alcohol group. The primary objective is to evaluate the superiority and duration of analgesic effects between these two methods. Clinical outcomes are assessed at baseline and at 1, 3, and 6 months post-procedure using the Numeric Rating Scale (NRS) for pain intensity, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for physical function, and the Short Form-12 (SF-12) for health-related quality of life.\n\nThe results of this study aim to provide high-quality evidence regarding the comparative effectiveness and long-term outcomes of genicular nerve RF and alcohol neurolysis in the clinical management of chronic knee osteoarthritis pain.",[28,29,30],"Knee Osteoarthristis","Radiofrequency Ablation","NEUROLYSIS","NOT_YET_RECRUITING","2026-04-10",{"date":34,"type":35},"2026-04-17","ACTUAL",{"date":37,"type":22},"2026-05-01",{"date":39,"type":22},"2026-12-30",{"name":41,"class":42},"Sakarya University","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100600696","phase-1-periprostatic-neurolysis-in-prostate-cancer-100600696","NCT07100847","Periprostatic Neurolysis in Prostate Cancer","Phase 1b Window of Opportunity Study of Peri-prostatic Neurolysis in High-risk Localized Prostate Cancer","Inclusion criteria:\n\nHigh risk prostate cancer as defined by NCCN criteria Desires surgical disease treatment (radical prostatectomy) Surgical candidate (for radical prostatectomy)\n\n≤cT3a on MRI No seminal vesicle, lymph node, or metastatic disease on PSMA PET No prior prostate cancer treatment (including androgen deprivation therapy, radiation therapy, focal therapy, cryo therapy)","MALE","18 Years",{"count":53,"type":22},21,[55],"PHASE1","The purpose of this research study is to assess whether inhibiting nerve activity to the prostate delays progression of disease in men with high-risk clinical features for prostate cancer. Prostate cancer has been shown to invade nerves, a mechanism that is thought to be involved in prostate cancer spread in men with high-risk cancer. When nerve activity to the prostate is blocked in mice with prostate cancer, prostate cancer growth and spread are inhibited. In a previous study we showed that doing so in humans was safe and may have anticancer therapeutic effect. In this study we will test whether one versus two injections of nerve blocking agent is more effective at reducing nerves in the prostate and whether it will slow\u002Fstop spread of prostate cancer after treatment.",[58,59,60,30],"PROSTATE CANCER","NERVES","NEUROBIOLOGY OF CANCER",[62],"HIGH RISK LOCALIZED PROSTATE CANCER","RECRUITING","2025-09-07",{"date":66,"type":35},"2025-09-09",{"date":68,"type":35},"2025-08-15",{"date":70,"type":22},"2028-08",{"name":72,"class":42},"University of Texas Southwestern Medical Center",1]